|

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

RECRUITINGSponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Actively Recruiting
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
Started2024-03-22
Est. completion2030-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06800612

Summary

retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;
* Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;
* Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.

Exclusion Criteria:

* no exclusion criteria

Conditions7

Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer, MetastaticCancerCervical CarcinomaEndometrial CancerOvarian Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.